Abstract
The main principle of treatment of hemophilia is the replacement of the deficient coagulation factor with plasma-derived or recombinant products. The goal of replacement therapy may be either the prompt arrest of bleeding (episodic or on demand treatment) or its prevention through the regular administration of factor (prophylaxis).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Nilsson IM, Hedner U, Ahlberg A. Hemophilia prophylaxis in Sweden. Acta Paediat Scand 65: 129–135, 1976.
Ahlberg A. Haemophilia in Sweden. VII. Incidence, treatment and prophylaxis of arthropathy and other musculo-skeletal manifestations of haemophlia A and B. Acta Orthop Scand 77: 1–98, 1965).
Petrini P, Blomback M, Egberg N, Lindvall N. Prophylaxis with factor concentrates in preventing hemophilic arthropathy. Am J Pediat Hematol Oncol 13: 280–287, 1991.
Nilsson IM, Berntorp E, Lofquist T, Pettersson H. Twenty-five years’ experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 232: 25–32, 1992.
Blanchette VS, Al-Musa A, Stain AM, Ingram J, Fille RM. Central venous access devices in children with hemophilia: an up-date. Blood Coag Fibrinol 8: S11–S14, 1997.
Ljung R, van den Berg M, Petrini P, Tengbom L, Scheibel E, Kekomaki R, Effenber W. Prot-ACath usage in children with haemophilia: experience of 53 cases. Acta Paedit 87:1051–1054, 1998.
Lofquist T, Nilsson IM, Berntorp E, Pettersson H. Haemophilia prophylaxis in young patients. A long-term follow-up. J Intern Med 241: 395–400 1997.
Bemtorp E. Methods of hemophilia care delivery: regular prophylaxis vs. episodic treatment. Haemophilia 1: 3–7, 1995.
van den Berg HM, Nieuwenhuis HK, Mauser-Bunchoten EP, Rosendeal G. Haemophilia prophylaxis in the Netherlands. Sem Haematol 31: 13–15 (suppl. 2), 1994.
Liesner Rj, Hair K, Hann IM. The impact of prophylactic treatment on children with severe haemophilia. Br J Haem 92: 973–978, 1996.
Lusher J. Prophylaxis in children with hemophilia: is it the optimal treatment? Thromb Hemostats 78: 726–729, 1997.
Manco-Johnson MJ, Nuss R, Geraghty S, Funk S, Kilcoyne R. Results of secondary prophylaxis in children with severe hemophilia. Am J Hematol 47: 113–117, 1994.
Smith PS, Teutsch SM, Schaffer PA, Rolka H, Evatt B. Episodic versus prophylactic infusions for hemophilia A: a cost-effectiveness analysis. J Paediat 129: 424–431, 1996.
Szucs TD, Offner A, Schramm W. Socioeconomic impact of haemophilia care: results of a pilot study. Haemophilia 2: 211–217, 1996.
Bohm RL, Avom J, Glynn RJ, Choodnovsky I, Haschemeyer R, Aledort LM. Prophylactic use of factor VIII: an economic evaluation. Thromb Haemostas 79: 932–937, 1998.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2001 Springer Science+Business Media New York
About this chapter
Cite this chapter
Mannucci, P.M., Mendolicchio, L., Gringeri, A. (2001). Use of Prophylaxis to Prevent Complications of Hemophilia. In: Monroe, D.M., Hedner, U., Hoffman, M.R., Negrier, C., Savidge, G.F., White, G.C. (eds) Hemophilia Care in the New Millennium. Advances in Experimental Medicine and Biology, vol 489. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-1277-6_5
Download citation
DOI: https://doi.org/10.1007/978-1-4615-1277-6_5
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-5474-1
Online ISBN: 978-1-4615-1277-6
eBook Packages: Springer Book Archive